Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
MetaVia ( (MTVA) ) just unveiled an update.
MetaVia Inc., a clinical-stage biotechnology company specializing in therapies for cardiometabolic diseases such as obesity and MASH, is advancing a pipeline led by DA-1726, a dual GLP-1/glucagon oxyntomodulin analog, and vanoglipel, a GPR119 agonist designed for standalone or combination use in liver and metabolic disorders. Both assets have produced encouraging results in early clinical studies and preclinical models, underscoring MetaVia’s ambition to deliver differentiated treatments in the rapidly expanding obesity and metabolic disease markets.
On May 18, 2026, MetaVia announced that three late-breaking abstracts featuring DA-1726 and vanoglipel were accepted for poster presentation at the American Diabetes Association’s 2026 Scientific Sessions, to be held June 5–8 in New Orleans. The data include higher-dose Phase 1 results for DA-1726 in obesity and preclinical studies showing synergistic effects of vanoglipel in combination with resmetirom for MASH and metformin for type 2 diabetes, developments that highlight the breadth of MetaVia’s cardiometabolic portfolio and may enhance its visibility and credibility among clinicians, partners and investors.
The most recent analyst rating on (MTVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing losses, and continued cash burn) and bearish technicals (trading below major moving averages with negative MACD). Offsetting factors include low leverage on the balance sheet and a supportive flow of positive clinical/program milestones and financing, but these are not enough to overcome the current fundamentals and trend.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on cardiometabolic diseases, developing therapies for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Its lead programs include DA-1726, a once-weekly dual GLP-1/glucagon oxyntomodulin analog showing strong weight-loss and metabolic effects, and vanoglipel, a GPR119 agonist aimed at improving glucose, lipid metabolism and liver health in MASH and type 2 diabetes.
Both candidates have shown promising signals in early-stage trials and preclinical models, with DA-1726 demonstrating best-in-class potential on weight loss and glucose control, and vanoglipel exhibiting direct hepatic action, reductions in steatosis and inflammation, and good tolerability. This positions MetaVia as an emerging player in the competitive obesity and liver disease therapeutics market, targeting conditions with significant unmet medical need and large commercial potential.
Average Trading Volume: 144,528
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.73M
See more insights into MTVA stock on TipRanks’ Stock Analysis page.